Lily Zou
Directeur/Membre du Conseil chez Glycotest, Inc.
Profil
Lily Zou is currently a Director at Glycotest, Inc. She was previously the Chief Executive Officer at Fosun Pharma USA, Inc. and an Independent Director at Nature's Sunshine Products, Inc. She also served as the Executive Director-Business Development at Sandoz, Inc. from 2009 to 2017.
Dr. Zou holds a doctorate degree from Cornell University, an undergraduate degree from Beijing University of Technology, and an MBA from MIT Sloan School of Management.
Postes actifs de Lily Zou
| Sociétés | Poste | Début |
|---|---|---|
Glycotest, Inc.
 Glycotest, Inc. Electronic Equipment/InstrumentsElectronic Technology Glycotest, Inc. develops diagnostic markers for liver disease diagnosis. It offers disease signal chemistry (glycoprotein fucosylation) present in liver cancers and fibrosis-cirrhosis but absent in healthy individuals. The company was founded in 2012 and is headquartered in New York, NY. | Directeur/Membre du Conseil | - |
Anciens postes connus de Lily Zou
| Sociétés | Poste | Fin |
|---|---|---|
| NATURE'S SUNSHINE PRODUCTS, INC. | Directeur/Membre du Conseil | 20/09/2021 |
Sandoz, Inc.
 Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Corporate Officer/Principal | 01/01/2017 |
Fosun Pharma USA, Inc.
 Fosun Pharma USA, Inc. Pharmaceuticals: MajorHealth Technology Fosun Pharma USA, Inc. is a fast-growing pharmaceutical company that was founded in 2017. The private company is based in Princeton, NJ. The company, which is a subsidiary of Fosun Pharma, continually works to enhance its existing portfolio of specialty pharmaceutical injectables and to build its pipeline with both innovative and generic pharmaceutical drugs. Fosun Pharma USA is dedicated to bringing products to market to improve patient access to medicine and innovation. Rong Yang has been the CEO of the company since 2022. | Directeur Général | - |
Formation de Lily Zou
| Cornell University | Doctorate Degree |
| Beijing University of Technology | Undergraduate Degree |
| MIT Sloan School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NATURE'S SUNSHINE PRODUCTS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Sandoz, Inc.
Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | Health Technology |
Glycotest, Inc.
Glycotest, Inc. Electronic Equipment/InstrumentsElectronic Technology Glycotest, Inc. develops diagnostic markers for liver disease diagnosis. It offers disease signal chemistry (glycoprotein fucosylation) present in liver cancers and fibrosis-cirrhosis but absent in healthy individuals. The company was founded in 2012 and is headquartered in New York, NY. | Electronic Technology |
Fosun Pharma USA, Inc.
Fosun Pharma USA, Inc. Pharmaceuticals: MajorHealth Technology Fosun Pharma USA, Inc. is a fast-growing pharmaceutical company that was founded in 2017. The private company is based in Princeton, NJ. The company, which is a subsidiary of Fosun Pharma, continually works to enhance its existing portfolio of specialty pharmaceutical injectables and to build its pipeline with both innovative and generic pharmaceutical drugs. Fosun Pharma USA is dedicated to bringing products to market to improve patient access to medicine and innovation. Rong Yang has been the CEO of the company since 2022. | Health Technology |